A5038757936- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
- Immune cells in cancer
- Nanoparticle-Based Drug Delivery
- Pancreatic and Hepatic Oncology Research
- Cancer, Stress, Anesthesia, and Immune Response
- Nanoplatforms for cancer theranostics
Renji Hospital
2021-2025
Shanghai Jiao Tong University
2021-2025
Jiangmen Central Hospital
2023
State Key Laboratory of Oncogene and Related Genes
2021
Background: Diffuse Gastric Cancer (DGC) is a highly aggressive form of gastric cancer with poor prognosis. Oxaliplatin (OX) one the first-line chemotherapeutic agents for treatment cancer. However, some patients DGC do not benefit from OX therapy. Resibufogenin (RBF), main active components Chinese medicine Huachansu, has demonstrated significant anti-cancer effects. Nevertheless, potential RBF to enhance sensitivity in and its underlying mechanisms have been reported. Objective: The aim...
Tumor vasculature constitutes a formidable hurdle for the efficient delivery of cancer nanomedicine into tumors. The leverage passive pathway through inter-endothelial gaps in tumor blood vessels might account limited extravasation microenvironment (TME). Herein, Annexin A1 antibody-installed mesoporous organosilica nanoplatforms carrying immunotherapeutics anti-PD-L1 antibody (aPD-L1) and Indoximod are developed to target at caveolar Annexin-A1 protein luminal endothelial cells trigger...
Background. The morbidity and mortality of gastric cancer are high in China. There challenges to develop precise individualized drug regimens for patients with after a standard treatment. Choosing the most appropriate anticancer patient developing resistance is very important improve patient’s prognosis. MiniPDX has been widely used as new reliable preclinical research model predict sensitivity drugs. Methods. OncoVee® system developed by Shanghai LIDE Biotech Co., Ltd. was establish models...
Background. Human epidermal growth factor receptor 2 (HER2) is a member of the large ErbB family and an important oncogene in many solid tumors. Pyrotinib has been approved for treatment HER2-positive, recurrent, or metastatic breast cancer. However, there are very few clinical studies on pyrotinib other HER2-positive Therefore, more evidence research impendently needed to shepherd pyrotinib-based therapy nonbreast advanced Patients Methods. We performed retrospective analysis tumors...
e15514 Background: Trophoblast cell-surface antigen 2 (TROP2), a transmembrane glycoprotein in epithelial cells, is implicated malignant progression, notably breast cancer therapy. However, the clinicopathologic aspects of TROP2 colorectal (CRC) are unclear. This study aims to explore association between expression and clinicopathological features CRC investigate inhibitory effects anti-TROP2 antibody-SN-38 conjugate (ADC-TROP2) on colon cells. Methods: A retrospective analysis 1296 patients...
e15592 Background: The treatment in patients with metastatic colorectal cancer (mCRC) have limited effectiveness and options. And research findings revealed that combining anti-angiogenesis inhibitors programmed death-1(PD-1) can reverse the immunosuppressive tumor microenvironment synergistically enhance antitumor immune response. goal of study was to add more real-world data prove clinical efficacy safety this regimen. Methods: We conducted a Real-World observation by comparison...
Abstract Background: The treatment in patients with metastatic colorectal cancer (mCRC) has limited options. About 90% of CRC mismatch repair proficient/microsatellite stable (pMMR/MSS) tumors, were almost unresponsive to PD-1 antibody treatment. This report shows that a patient pMMR/MSS mCRC achieved significant response from tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR) family (VEGFR-1,2,3) (fruquintinib) plus anti-PD-1 immunotherapy the third...
Abstract Background Gastric cancer (GC) remains one of the most common malignancieswith poor prognosis worldwide. Immunotherapy based on PD-1/PD-L1 immune checkpoints has achieved robust and durable responses in various types cancer, but only a subset gastric patients benefits from it.Myeloid-derived suppressor cells (MDSCs) have been demonstrated to suppress antitumor immunityand induceresistanceto blockade immunotherapy. Death receptor5 (DR5), receptor TNF-related apoptosis-inducing...